In silico methods for immunogenicity risk assessment and human homology screening for therapeutic antibodies
In silico immunogenicity risk assessment has been an important step in the development path for many biologic therapeutics, including monoclonal antibodies. Even if the source of a given biologic is ‘fully human’, T cell epitopes that are contained in the sequences of the biologic may activate the i...
Saved in:
Main Authors: | Aimee E. Mattei, Andres H. Gutierrez, Soorya Seshadri, Jacob Tivin, Matt Ardito, Amy S. Rosenberg, William D. Martin, Anne S. De Groot |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2024-12-01
|
Series: | mAbs |
Subjects: | |
Online Access: | https://www.tandfonline.com/doi/10.1080/19420862.2024.2333729 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
T and B cell epitope analysis for the immunogenicity evaluation and mitigation of antibody-based therapeutics
by: Ruoxuan Sun, et al.
Published: (2024-12-01) -
Proceedings of the 14th European immunogenicity platform open symposium on immunogenicity of biopharmaceuticals
by: Sophie Tourdot, et al.
Published: (2024-12-01) -
Editorial: The immune response to therapeutic antibodies
by: Michael G. Tovey, et al.
Published: (2025-02-01) -
Improving the integrity and reproducibility of research that uses antibodies: a technical, data sharing, behavioral and policy challenge
by: M. Biddle, et al.
Published: (2024-12-01) -
Nonclinical immunogenicity risk assessment for knobs-into-holes bispecific IgG1 antibodies
by: Wen-Ting K. Tsai, et al.
Published: (2024-12-01)